Edition:
India

People: Alibaba Health Information Technology Ltd (0241.HK)

0241.HK on Hong Kong Stock

8.73HKD
16 Dec 2019
Change (% chg)

HK$0.05 (+0.58%)
Prev Close
HK$8.68
Open
HK$8.70
Day's High
HK$8.87
Day's Low
HK$8.65
Volume
9,046,167
Avg. Vol
13,232,690
52-wk High
HK$10.38
52-wk Low
HK$5.84

Huang, Yi Fei 

Ms. Huang Yi Fei is Non-Executive Independent Director of the Company. Ms. Huang is currently a General Partner at BVCF Management. Ms. Huang has over 20 years of investment banking experience in the United States and Hong Kong. Prior to joining BVCF, she was Head of Emerging Asia Healthcare Investment Banking at J.P. Morgan. Before J.P. Morgan, she led Deutsche Bank Asia’s healthcare investment banking coverage. Ms. Huang gained biotech industry experience at Amgen. During her time in investment banking, Ms. Huang worked with companies and investors across Asia Pacific as well as global multinational companies and institutional investors. Her coverage included all subsectors of healthcare — pharmaceutical, biotech, medtech and services. She advised on multiple cross-border mergers and acquisitions and different stages of capital raising. Ms. Huang is a member of the Biotech Advisory Panel of the Stock Exchange and a member of the Admission Panel of the Incu-Bio Incubation Programme of the Hong Kong Science and Technology Parks Corporation. She is also co-Chairman of the Healthcare Committee of the Hong Kong Venture Capital and Private Equity Association. Ms. Huang obtained a Master of Science Degree in Engineering-Economic Systems from Stanford University in June 1996 and a Master of Business Administration from The Wharton School, University of Pennsylvania in June 2003, respectively.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --